Establishing gene regulatory networks from Parkinson's disease risk loci

Gene regulatory networks in PD

Sophie L. Farrow¹, William Schierding^{1,2}, Sreemol Gokuladhas¹, Evgeniia Golovina¹, Tayaza Fadason^{1,2}, Antony A. Cooper^{3,4*}, Justin M. O'Sullivan^{1,2,5,6*}

1 Liggins Institute, The University of Auckland, Auckland, New Zealand

2 The Maurice Wilkins Centre, The University of Auckland, Auckland, New Zealand

3 Australian Parkinson's Mission, Garvan Institute of Medical Research, Sydney, New South Wales, Australia

4 St Vincent's Clinical School, UNSW Sydney, Sydney, New South Wales, Australia

5 Brain Research New Zealand, The University of Auckland, Auckland, New Zealand

6 MRC Lifecourse Epidemiology Unit, University of Southampton, United Kingdom

*corresponding co-senior authors.

Abstract

The latest meta-analysis of genome wide association studies (GWAS) identified 90 independent single nucleotide polymorphisms (SNPs) across 78 genomic regions associated with Parkinson's disease (PD), yet the mechanisms by which these variants influence the development of the disease remains largely elusive. To establish the functional gene regulatory networks associated with PD-SNPs, we utilised an approach combining spatial (chromosomal conformation capture) and functional (expression quantitative trait loci; eQTL) data. We identified 518 genes subject to regulation by 76 PD-SNPs across 49 tissues, that encompass 36 peripheral and 13 CNS tissues. Notably, one third of these genes were regulated via *trans*-acting mechanisms (distal; risk locus-gene separated by > 1Mb, or on different chromosomes). Of particular interest is the identification of a novel *trans*-eQTL-gene connection between rs10847864 and *SYNJ1* in the adult brain cortex, highlighting a convergence between familial studies and PD GWAS loci for *SYNJ1* (*PARK20*) for the first time. Furthermore, we identified 16 neuro-development specific eQTL-gene regulatory connections within the foetal cortex, consistent with hypotheses suggesting a neurodevelopmental involvement in the pathogenesis of PD. Through utilising Louvain clustering we extracted nine significant and highly intra-connected clusters within the entire gene regulatory network. The nine clusters are enriched for specific biological processes and pathways, some of which have not previously been associated with PD. Together, our results not only contribute to an overall understanding of the mechanisms and impact of specific combinations of PD-SNPs, but also highlight the potential impact gene regulatory networks may have when elucidating aetiological subtypes of PD.

Introduction

Parkinson's disease (PD) is considered to be primarily an idiopathic neurodegenerative disorder, with monogenic forms contributing to just 5-10% of all cases¹. However, the idiopathic nature of PD is being questioned, as evidence increasingly supports a complex involvement of genetics in the development of the majority of cases^{2,3}. Genome-wide association studies (GWAS) have identified >200 PD risk loci⁴, with 90 PD-associated Single Nucleotide Polymorphisms (PD-SNPs) across 78 risk loci reported in the largest meta-analysis to date⁵. As is typically observed with GWAS variants, the majority of the PD-SNPs are located within non-coding regions of the genome, with no direct or obvious influence on protein structure or function^{6,7}. Studies have shown that such non-coding disease-associated variants are more likely to be located within regulatory regions⁸, and thus contribute to risk through influencing gene regulation and expression, either locally or distally. These regulatory interactions are likely to be tissue specific, adding a further layer of complexity. Consequently, determining how these variants contribute to PD risk, both individually and in combination, poses a major scientific challenge^{9,10}.

Although PD is defined as a neurodegenerative disease, mounting evidence demonstrates the role of non-central nervous system (CNS) tissues in the development and presentation of such disorders (*i.e.* Huntington's¹¹ and PD^{12,13}). Both alpha-synuclein (α Syn) protein pathology and modulation of PD-related genes have been identified in peripheral tissues (*e.g.* the gastrointestinal tract and heart) of PD patients^{12,14–19}. The contribution of peripheral tissue in the origins of PD warrants further research, and thus the consideration of how PD-SNPs mediate risk should not be confined to tissues of the CNS.

Spatial gene regulatory interactions are hypothesized to be drivers of complex trait heritability²⁰, acting through both *cis*- (nearby) and *trans*- (distal; locus-gene separated by >

1Mb, or on different chromosomes) mechanisms (Figure 1)^{19,21,22}. These *cis*- and *trans*-acting elements can regulate the transcription of one or more genes, in a tissue specific manner, and are commonly detected in the form of expression quantitative trait loci (eQTL)²³. Genetic variation within elements of gene regulatory networks likely confer risk at different developmental stages, including during foetal neurodevelopment – a critical stage that has a growing body of support in neurodegenerative diseases²⁴.

Here we performed correlational analyses of experimentally derived data to identify eQTLs that physically connect PD-SNPs to the genes that they control, in three-dimensions, with the goal of understanding the putative functional impacts of known PD-SNPs²¹. The integration of spatial and eQTL data allows for the identification of *trans*-eQTL-gene associations²⁵, thereby nominating genes which have not previously been implicated in PD. Our analysis identified 518 genes subject to regulation by 76 PD-SNPs across 49 tissues. Further, clustering analysis of the entire gene network revealed nine significant, intra-connected clusters, enriched for both novel and known PD biological pathways, highlighting putative disease-causative molecular mechanisms and areas for future research.

Methods

Data and reference files

The 90 PD-SNPs (across 78 genomic regions; Supplementary table 1) investigated in this study were previously identified by a GWAS meta-analysis as being of genome wide significance ($p < 5 \times 10^{-8}$)⁵. The human genome reference sequence used in this study was GRCh38 (hg38).

Identification of eQTL-gene pairs

The contextualise developmental SNPs using 3D information (CoDeS3D)²¹ algorithm was used to identify genes whose transcript levels are putatively regulated by the 90 PD-SNPs. CoDeS3D integrates data on spatial interactions between genomic loci (Hi-C data; Supplementary table 2) with expression data (genotype-tissue expression database version 8; GTEx v8²⁶) to identify genes whose transcript levels are associated with a physical connection to the SNP (*i.e.* spatial eQTL).

Hi-C captures regions of the genome that are physically interacting, and can be covalently connected by a cross-linking agent²⁷. The hg38 reference genome was digitally digested with MboI, DpnII and HindIII to obtain all possible Hi-C fragment locations for the 90 PD-SNP loci. All identified SNP fragments (tagged by the PD-SNPs) were then queried against the Hi-C databases (70 different cell lines from 12 studies; Supplementary table 2) to identify distal fragments of DNA that spatially connect to the SNP loci. Spatial SNP-gene connections are established when the SNP-containing fragment spatially connects to a fragment that overlaps any region between the start and end of a gene as defined by GENCODE. There was no binning or padding around restriction fragments to obtain gene overlap. The resulting spatial SNP-gene pairs were subsequently used to query the GTEx v8 eQTL database²⁶ to

identify spatial SNP-gene pairs with significant eQTLs (both *cis*- and *trans*- acting eQTL; false discovery rate (FDR) adjusted $p < 0.05$).

We performed a ‘brain specific’ analysis by interrogating only the subset of Hi-C libraries derived from brain-specific cell lines (11 cell lines from 4 studies, highlighted in red in Supplementary table 2)^{28–31} and only expression data from the 13 brain-specific tissues in GTEx v8.

Identification of neurodevelopmental-specific eQTL-gene pairs

We performed a neurodevelopmental stage specific analysis by interrogating Hi-C libraries from foetal-specific brain cell lines (cortical plate neurons; germinal zone neurons; Supplementary table 2; datasets no. 1 and 2) with expression data from a foetal cortex eQTL dataset³².

Functional analysis of eQTL SNPs

SNPnexus v4³³ (<https://www.snp-nexus.org/v4/>; accessed 22/06/2020) was used to obtain known epigenomic annotations for the eQTL SNPs.

Probability of gene loss of function intolerance

The LOEUF (loss-of-function observed/expected upper bound fraction)³⁴ score for the genes, within the significant SNP-gene pairs, was obtained from gnomAD v2.1.1³⁵ (<https://gnomad.broadinstitute.org/>; accessed 21/07/2020) to determine the level of constraint on the identified genes.

Protein-protein interaction (PPI) and Modularity clustering

STRING³⁶ (Search Tool for Retrieval of Interaction Genes/proteins; <https://string-db.org>, accessed 22/07/2020) was queried to identify published information on interactions between genes, or their respective proteins. Only PPIs with a high confidence level (>0.700 , as defined in STRING) were used for this analysis. A Louvain method was used to determine the syntality of each node, following four different criteria: 1) immediate connection; 2)

shortest path (*i.e.* the minimum number of edges connecting any two nodes); 3) node acting as a bridge; 4) connections that nodes have in common. The proteins were then hierarchically clustered using the Louvain algorithm³⁷, clusters were defined as significant if $p < 0.05$.

Pathway analyses & literature search

The g:Profiler³⁸ database was used to identify enriched pathways. Queries were run on: 1) all genes' 2) the '*cis*'; and 3) the '*trans*' subsets of genes (*i.e.* genes regulated only in *cis*, or only in *trans*). PubMed was used to search (using "[gene name]" and Parkinson's") the published literature for all identified genes and known PD associations.

Additional analyses of genes and variants identified by Makarious et al

Makarious et al recently utilised a multi-modality approach to identify genetic and transcriptomic features that contribute to risk predictions of PD³⁹. They highlighted two SNPs (rs10835060 and rs4238361), and 29 genes. We performed CoDeS3D analysis on the two SNPs, across all Hi-C cell lines and GTEx tissues (as previously described). The resulting eQTL gene pairs, along with the 29 genes highlighted through transcriptomic analysis, were combined with our set of 523 genes. Louvain clustering and PPI analysis were re-run on this combined list of genes to see how or if the subset of genes co-locate within the networks.

URLs

CoDeS3D pipeline: <https://github.com/Genome3d/codes3d-v2>

gnomAD: <https://gnomad.broadinstitute.org/>

gProfiler: <https://biit.cs.ut.ee/gprofiler/>

UCSC: <https://genome.ucsc.edu/index.html>

STRING: <https://string-db.org/>

SNPNexus: <https://www.snp-nexus.org/>

Louvain clustering analysis: <https://github.com/Genome3d/PPI-network-analysis>

Data Availability

All data generated during this study are included in the supplementary information. Datasets analysed and tools used in this study were all derived from publicly available resources (See URLs).

Results

PD GWAS SNPs regulate the expression of > 500 genes

Nalls et al.⁵ identified 90 SNPs that were associated with PD at the level of genome-wide significance (Supplementary table 1), yet the mechanisms by which these variants influence the development of the disease remains largely elusive. We used the CoDeS3D algorithm²¹ to identify SNPs that have evidence of physical interaction with the gene as captured by Hi-C (Supplementary table 2) and also associate with changes in gene expression (hereafter eQTLs) and the genes whose transcript levels were affected (Figure 1).

76 (84%) of the 90 PD risk SNPs were identified as eQTLs associated with the regulation of 518 genes through 542 unique eQTL-gene pairs, across the 49 tissues (Table 1, Supplementary table 3). The 76 eQTLs were individually associated with the regulatory impacts of as few as one, or as many as 39 genes in *cis* and *trans* (Supplementary figure 1). We identified 178 of the 542 genes as being associated with PD through *trans*-eQTL-gene connections. We did not identify eQTL interactions for 14 of the 90 SNPs. Conversely, 8 of these 14 SNPs are annotated as being eQTLs in the IPDGC GWAS Locus Browser⁴⁰, and a further four are eQTLs in GTEx (Supplementary table 1). However, in these 12 instances, the eQTLs occur in *cis*- (*i.e.* within 1Mb) and are not supported by Hi-C data.

	PD SNPs	
	Brain specific*	All tissues*
No. SNPs	90	90
No. eQTL SNPs [#]	55	76
No. Genes [†]	165	518
No. eQTL-Gene pairs [‡]	167	542
No. <i>trans</i> eQTL-Gene pairs	30	178

Table 1: Summary statistics for the spatial eQTL-gene regulatory network for the 90 PD-SNPs. SNPs were downloaded from Nalls et al 2019 GWAS paper (download date: 18.06.2020). [#]eQTL SNPs were defined as having significant spatial interactions (FDR

≤ 0.05) with at least one gene. [¶]genes were those whose expression was shown to be affected by an eQTL SNP. [‡] The total number of SNP-gene pairs reflects interactions with $FDR \leq 0.05$ in at least one GTEx tissue. * For full list of tissues see Supplementary tables 3 and 4.

Consistent with observations for SNPs associated with other traits⁴¹, at least one *trans*-regulatory interaction was identified for 81.6% (62 of 76) of the eQTLs. Moreover, 92.7% (165 of 178) of these *trans*-eQTL-gene interactions were identified in only one tissue. By contrast, the *cis*- interactions were identified in eight tissues on average (range of 1 to 49 tissues). 11.8% of the eQTLs (9 of 76; Supplementary table 1) were exclusively involved in *trans*-regulatory interactions. *Trans*-eQTL interactions regulated 18.1% of the genes identified in the brain (30 out of 166; Supplementary table 4), and 32.8% of the genes amongst all 49 tissues (178 out of 518; Table 2; Supplementary table 3). Collectively, these results highlight the importance of looking beyond the nearest gene to identify the regulatory effects of disease-associated variants.

	Genes subject to <i>cis</i> - or <i>trans</i> - regulation	
	Brain specific*	All tissues*
<i>Cis</i> eQTL-gene pairs	136 (82.0%)	364 (67.2%)
<i>Trans</i> -intrachromosomal eQTL-gene pairs	10 (6.0%)	56 (10.3%)
<i>Trans</i> -interchromosomal eQTL-gene pairs	20 (12.0%)	122 (22.5%)

Table 2: Proportion of genes subject to *cis*- and *trans*- regulation. The proportion of eQTL-gene pairs that are either *cis*-, *trans*-intrachromosomal or *trans*-interchromosomal in (a) 13 GTEx brain-specific tissues and (b) all 49 GTEx tissues. Brain-specific indicates the eQTL dataset obtained through analysing Hi-C cell lines only from the brain, and eQTLs only from the brain tissues in GTEx. All-tissues indicates the eQTL dataset obtained through analysing all Hi-C cell lines, and eQTLs from all tissues in GTEx. There is a significant difference (Chi

square test p .value < 0.01) between brain tissues and all tissues for the proportions of the cis vs. trans eQTLs.

We reasoned that SNPs that are involved in eQTLs likely mark enhancer or promoter sites⁴². We queried SNPnexus³³ to identify those eQTLs that were marked by histone modifications or fell within open chromatin regions, as indicated by DNase accessibility. Consistent with our hypothesis, 91% (69 of 76) of the SNPs were marked by histone modifications associated with either enhancers (58) and/or promoters (27). 27.6% of the SNPs were within accessible chromatin (Supplementary table 5). Collectively, these results are consistent with the hypothesis that the loci marked by these eQTLs may be involved in the regulation of gene expression.

Pathway analysis was conducted on the complete set of 518 genes that were impacted by the eQTLs (Supplementary table 6). g:Profiler³⁸ identified significant ($\text{adj.}p < 0.05$) enrichment within 10 known biological pathways (g:GOST), including response to interferon-gamma, synaptic vesicle recycling and endocytosis.

The regulatory impact of PD-SNPs extends beyond the CNS

Although PD is considered a degenerative disease of the brain, it has become apparent that dysfunction and or alpha-synuclein pathology is observed in non-CNS tissues of PD patients^{13–15}. Our spatial eQTL analysis included an assessment of the tissue distribution of the effects of the identified eQTLs within 13 CNS and 36 peripheral tissues. We identified peripheral tissue-specific eQTLs for 28% of the PD-SNPs (21 of 76). Only 2 of the 76 PD-SNPs (i.e. rs10756907 – *SH3GL2*, brain cortex; rs873786 – *SLC26A1*, brain cerebellum) had eQTLs that impacted gene expression levels exclusively in the brain. This supports a possible role for peripheral tissues in PD risk (Supplementary figure 3).

The ability to detect eQTLs in specific tissues is known to correlate with tissue sample size within GTEx⁴³. Consistent with this, we identified highly significant correlations between tissue sample numbers and a) all-eQTLs in the brain tissues (Figure 2a; identified using brain specific Hi-C and eQTL data; Supplementary Table 4); and b) all tissues (i.e. the 49 tissues included within GTEx; Figure 2e). These highly significant correlations remained when analysing the *cis*-eQTL subsets in the brain ($R = 0.93$, $p = 3.6 \times 10^{-6}$; Figure 2b), and all tissues ($R = 0.9$, $p < 2.2 \times 10^{-16}$; Figure 2f). Similarly, the correlation was evident for *trans*-intrachromosomal eQTLs detected in all tissues ($R = 0.67$, $p < 1.8 \times 10^{-6}$; Figure 2g). By contrast, there was no observable correlation between the number of *trans*-interchromosomal interactions and tissue sample number (Figure 2d,h). The substantia nigra and brain cerebellar hemisphere exhibited more *trans*-interchromosomal-eQTLs (Figure 2d), while the thyroid exhibited more eQTLs than expected across all three categories (Figure 2e-h).

Genes subject to *trans*-regulation by PD-SNPs are more likely to be intolerant to loss-of-function mutations

Genes that are intolerant to inactivation by loss-of-function variants are deemed essential for healthy development⁴⁴. Intolerance to loss of function variants leaves changes to regulation as one of the few mechanisms that can be modified to introduce variation at a population level. The 117 *trans*-interchromosomal-eQTL regulated genes were significantly ($p < 0.01$, Kruskal-Wallis test) more intolerant to loss-of-function mutations (LOEUF 0.42 [median]; a low LOEUF score is indicative of evolutionary constraint) than those regulated by *cis*- or *trans*-intrachromosomal acting eQTLs (LOEUF 0.83 and 0.85 respectively [median]; Figure 3; Supplementary table 7). This result is consistent with earlier observations that *trans*-eQTLs are enriched in regulating constrained genes with low LOEUF scores¹⁹.

PD GWAS SNPs regulate expression of a subset of genes within the foetal cortex

Emerging evidence suggests PD has a neuro-developmental aspect⁴⁸, similar to recent observations in Huntington's disease²⁴. Therefore, we analysed the regulatory impacts of the PD-SNPs using foetal cell line Hi-C (i.e. cortical plate neurons and germinal zone neurons²⁹) and foetal cortex eQTL datasets³² (Supplementary table 8). 33 genes were found to be regulated by 22 PD-SNPs in the foetal cortex. Of these, sixteen genes were regulated by eQTLs involving PD-SNPs in the foetal cortex, without evidence of any eQTLs in adult brain tissues (Figure 4; Supplementary table 4). Ten genes were affected by eQTLs involving PD-SNPs in both the foetal and adult cortex, with effect sizes that were similar in both (Figure 4). Finally, seven genes were regulated by *cis*-eQTLs in the foetal cortex and adult non-cortical brain tissues (Figure 4). These findings are consistent with the hypothesis that development-stage specific eQTL patterns impact on disease-relevant mechanisms and thus may contribute to the proposed temporal phases of PD pathogenesis⁴⁷.

Louvain clustering highlights nine intra-connected protein clusters, enriched for disease-relevant, biological pathways

Network representations of complex datasets can aid the identification of biological relationships that are often not identified by enrichment analyses⁴⁸. We used a Louvain clustering algorithm to identify clusters of interacting genes and proteins from within a Protein-Protein Interaction Network (PPIN) generated from the 523 eQTL regulated genes (518 adult tissue eQTLs and the 5 unique foetal cortex eQTLs; Supplementary table 9). Nine significant ($p < 0.05$) clusters consisting of 122 genes were identified within the high-confidence PPIN (Figure 5). The genes within each cluster were regulated by between 5 and 18 PD-SNPs (Supplementary table 9) and every cluster contained at least two genes that were

co-regulated by a single SNP (Supplementary figure 4). Notably, genes that were subject to *trans*-acting eQTLs were central to the definition and identification of several clusters (Figure 5). Pathway analysis (g:Profiler) of the genes within the individual clusters revealed enrichment in categories that included immunological surveillance (cluster 7), synaptic vesicle recycling (cluster 5) and microtubule polymerisation (cluster 3) (Supplementary table 10).

Makarious et al recently used a multi-modal machine learning approach, incorporating multi-omics datasets, to inform and improve predictions of PD³⁹. Beyond the 90 GWAS SNP signals (which collectively were the top genetic feature), they also identified rs10835060 and rs4238361 as two SNPs that impact on PD biology. CoDeS3D analysis identified eQTLs for both rs10835060 (*KRTAP5-AS1*, *CCDC88A*, *KRTAP5-5*, *BRSK2*) and rs4238361 (*USP47*; and *RP11-507B12.2* and *RP11-259A24.1*) (Supplementary table 11). Notably, *BRSK2* co-locates with cluster 2 through an established interaction with the Tau encoding *MAPT* gene⁴⁹. The model also highlighted 29 genes through transcriptomic analysis. Three of these genes (*MMP9*, *TRIM4* and *SYS1*) integrate into clusters 1, 4 and 5, respectively (Supplementary figure 5). The co-location of genes and eQTLs, identified as being important for PD diagnosis³⁹, within the nine clusters supports the potential importance of the gene-gene interactions and enriched pathways in PD.

402 genes did not segregate in the nine clusters. Of note, 211 of the 402 genes (52.5%) had not previously been associated with PD GWAS loci (iPDGC PD browser⁴⁰). Of the 211, 123 genes were regulated by *trans*-eQTL-gene connections. Notably, iPDGC identified five genes (*DNAIL1*, *EYA4*, *LYVE1*, *MYO5B*, *PDZRN4*) as being regulated by *cis*-eQTLs yet. These five genes were exclusively identified through *trans*-eQTL regulatory connections in our analysis.

Discussion

Assigning functionality to PD-SNPs is a critical step towards determining how they contribute to the risk of PD development. In this study, we identified 518 genes whose expression was regulated in *cis* or *trans* by PD-SNPs, and the tissues where this regulation occurs. We also demonstrated that 22 PD-SNPs impact the regulation of a subset of 16 genes solely in the foetal cortex, and a further 10 genes in both the foetal and adult cortex. Of all 523 identified genes, a subset of 122 *cis*- and *trans*- regulated genes formed nine clusters within a protein:protein interaction network that were enriched for specific biological pathways, some of which have not been previously associated with PD. Our findings support the hypothesis that both *cis*- and *trans*- dysregulation of gene expression contributes to the risk of PD and provide insight into possible disease-causing mechanisms.

SYNJI encodes synaptojanin-1, a presynaptic phosphoinositide phosphatase that dephosphorylates PI(4,5)P₂ to trigger the removal of the clathrin coat during synaptic vesicle recycling⁵⁰. *SYNJI* is a highly constrained gene (LOEUF score = 0.33) and rare missense mutations in *SYNJI* have been linked to early-onset Parkinsonism⁵¹. Despite this, GWA studies have not identified any SNPs proximal to *SYNJI* as being significantly associated with PD, nor have they attributed any significant PD SNP (near or far) to *SYNJI*. Critically, we identified that the PD-associated SNP rs10847864 acts as a *trans*-acting eQTL for *SYNJI* expression. rs10847864 is intronic to, and also acts as a *cis*-eQTL with, *HIP1R*, another gene that is involved in clathrin mediated endocytosis^{52–54}. Our discovery of the *trans*-eQTL-*SYNJI* connection merges observations from population level (i.e. GWAS) and familial studies, reinforcing the potential importance of *SYNJI* in PD.

Our analysis identified *trans*-eQTLs for approximately two-thirds of the known PD-SNPs. Of note, *RAI14* (retinoic acid induced 14) is regulated by two *trans*-eQTLs, involving two independent PD-SNPs (rs2251086, chr.15 and rs55818311, chr.19). Although not yet directly linked to PD, *RAI14* (and its encoded protein ankycorbin) has been shown to play a role in the inflammatory response in glial cells⁵⁵, and in the establishment of neuronal morphology⁵⁶; both of which are pathways of known importance in PD pathogenesis⁵⁷. Retinoic acid, a regulator of *RAI14* (one of multiple roles of retinoic acid), is being explored as a potential therapeutic target for PD⁵⁸.

Our results provide support for the role of peripheral tissues in PD, notably the oesophagus and thyroid. Firstly, the oesophagus is enriched for *cis* and *trans* regulatory eQTLs. rs76904798 (PD odds ratio (OR) = 1.155) is an eQTL that upregulates *LRRK2* expression in 19 peripheral tissues, including in the oesophagus. Notably, this *cis*-eQTL with *LRRK2* is not identified in any CNS tissues. Secondly, we identified the thyroid tissue as being enriched for eQTLs, many of which were not represented in CNS tissues. The thyroid is a component of the dopaminergic system and hypothalamic–pituitary–thyroid axis network⁶¹. A potential link between thyroid hormone disorders, PD risk, and symptom severity has been suggested⁶². Specifically, one study identified patients with hypothyroidism to have a two-fold elevated risk of developing PD⁶³. Collectively, these findings support the growing body of evidence for the importance of the oesophagus^{64,65} and thyroid⁶² in PD.

We hypothesised that genes regulated by PD-SNPs in foetal cortical tissue may contribute to potential neurodevelopmental aspects of PD^{24,45,46}. Sixteen genes were regulated by PD-SNP eQTLs within the foetal cortex. Two of these genes, *CNTNAP1* and *GALC* are particularly notable. *CNTNAP1* encodes Caspr1, a Neurexin family membrane protein. Reductions in

Caspr1 concentrations delay cortical neuron and astrocyte formation in the mouse developing cerebral cortex⁶⁶. *GALC* encodes a lysosomal galactosylceramidase that ensures normal turnover of myelin⁶⁷ and has been linked to neuronal vulnerability⁶⁸. While connections between the remaining 14 genes and PD development are less clear, we speculate that SNP mediated regulation of these genes specific to the foetal cortex may contribute to early neuro-developmental disturbances that render an individual more susceptible to PD.

Our analyses identified nine clusters that are enriched for specific biological processes and pathways, some of which have not previously been associated with PD. Dysregulated expression of the components within these pathways is potentially the basis of the risk conferred by the PD-SNPs. The clusters aid in understanding how PD SNPs mechanistically contribute to disease risk, and some interesting points can be drawn from these. For example, genes within cluster 6 are enriched for functions in DNA replication and repair, a pathway previously associated with the development of other neurodegenerative diseases⁶⁹. Notably, *BRCA1* and *RPA2* (both previously linked to DNA damage response and repair^{70,71}) are regulated in *trans* by PD-SNPs (rs11950533; rs9568188; rs62053943) and are central to cluster 6. It is notable that cluster 6 contains several factors associated with PARP1 activity (e.g. the PARP1 binding protein (PARPBP) and *BRCA1*) that link this cluster to the repair of SSBs which are enriched at neuronal enhancers in post-mitotic neurons⁷². A further example is the regulation of autophagy initiation by PD-SNPs, highlighted in cluster 8. Three interacting proteins within cluster 8, encoded by *VMPI*, *BECN1*, and *ATG14* are each regulated by a different PD-SNP (rs12951632 chr. 17; rs11158026 chr. 14; rs10748818 chr. 10; Supplementary table 3), including a *trans*-eQTL connection regulating *VMPI*. rs12951632 (OR= 0.93) and rs11158026 (OR= 0.919) are protective PD-SNPs that respectively increase *BECN1* and *ATG14* expression, two interacting core components of the

PI3-kinase complex, required for autophagosome formation⁷³. Individuals with both of these variants would potentially have increased autophagic capacity relative to individuals with one variant.

The genes in cluster 7 are strongly enriched for antigen processing and presentation – which is increasingly being implicated in the progression of PD⁷⁴. Both rs504594 and rs9261484 are associated with a reduced risk of developing PD (OR = 0.8457 and OR = 0.9385 respectively). We identified a spatial eQTL between rs504594 and *HLA-DRB1* in both the foetal cortex and adult brain (including cortex and SN), implicating this regulatory eQTL-gene connection in both the neurodevelopment and neurodegenerative stages of PD. Interestingly, rs504594 (previous ID: rs112485776) was recently validated in a SNP-level meta-analysis (OR = 0.87), with results displaying no residual HLA effect in adults after adjusting for the SNP⁷⁵. Instead, three amino acid polymorphisms within the *HLA-DRB1* gene were identified as drivers of the association between the HLA region and PD risk⁷⁵. We agree that the impacts of rs504594 are contingent upon the *HLA-DRB1* allele - both in terms of regulation and protein sequence. We contend that the effects of the rs504594 eQTL are developmental. Future studies must untangle these developmental effects and identify the neurodevelopmental stages that may prime certain individuals to be more vulnerable to later triggering mechanisms. We note that such interpretation should be taken with caution given the highly polymorphic nature of the HLA-region.

We acknowledge several limitations to our analysis. Firstly, the Hi-C cohort and GTEx libraries were generated from unrelated samples that were not age or gender matched. Secondly, the sampled donors in GTEx are predominantly of European descent, limiting the significance of our findings to this ethnicity. However, the GWAS cohort also used

individuals of European ancestry, meaning for this analysis the datasets were congruent. Thirdly, our eQTL analysis assumes that mRNA concentration correlates directly with protein levels. While it is true that protein levels are to some extent determined by their mRNA concentration, there are many post-transcriptional processes that can lead to a deviation from the expected correlation⁷⁶. The fourth limitation is that eQTL data represent composite datasets across developmental periods (e.g. foetal samples were aged from 14-21 weeks post-conception and the adult samples were from individuals aged 21-70 years). Despite such limitations, the identification of *trans*-eQTLs is a particular strength of our methodology, relying on captured contacts within the genome organisation to reduce the impact of multiple testing correction. As such, we contend that these limitations do not invalidate the significance of our findings of *trans*-acting eQTLs and the genes that they impact.

Conclusions

Understanding the functional impact of PD-SNPs is critical to our understanding of how these variants contribute to the development and clinical presentation of PD. Our functional interpretation of PD-associated SNPs integrates individual loci into a gene regulatory network, which includes genes with and without prior PD associations. The regulatory network includes clusters, and within them genes, that are enriched for biological functions that have known, putative or previously unknown roles in PD. Development-specific changes to this network (within the foetal cortex) are suggestive of roles for neurodevelopmental changes being early contributors to PD disease risk. Similarly, enrichments for regulatory changes within peripheral tissues may indicate a greater role for these tissues in PD than is currently appreciated. Collectively, our findings not only contribute to an overall understanding of the multiple biological pathways associated with PD risk loci, but also

highlight the potential utility of gene regulatory networks when considering etiological subtypes of PD.

Acknowledgements

SF, WS, TF, AC, and JOS were funded by the Michael J Fox Foundation for Parkinson's research and the Silverstein Foundation for Parkinson's with GBA – grant ID 16229 to JOS. SF and TF were funded by the Dines Family Charitable Trust. AC received grant funding from the Australian government. SG was funded by an MBIE Catalyst Grant (The New Zealand-Australia LifeCourse Collaboration on Genes, Environment, Nutrition and Obesity (GENO); UOAX1611). EG was funded by University of Auckland Doctoral Scholarship.

Author Contributions

SF performed analyses and wrote the manuscript. TF and EG contributed to the preparation of eQTL and Hi-C datasets used in the manuscript. TF and WS contributed to the development of CoDeS3D. SG contributed to the network analysis script and the associated dataset. TF, EG, and SG all commented on the manuscript. WS and AC advised on the study and co-wrote the manuscript. JOS led the study and co-wrote the manuscript.

Competing Interests Statement

The authors declare no competing interests

Supplementary Material

Supplementary tables are available at:

https://github.com/sfar956/PDGWAS_regulatorynetworks

References

1. Bandres-Ciga, S., Diez-Fairen, M., Kim, J. J. & Singleton, A. B. Genetics of Parkinson's disease: An introspection of its journey towards precision medicine. *Neurobiology of Disease* **137**, 104782 (2020).
2. Billingsley, K. J. *et al.* Mitochondria function associated genes contribute to Parkinson's Disease risk and later age at onset. *npj Park. Dis.* **5**, 1–9 (2019).
3. Blauwendraat, C., Nalls, M. A. & Singleton, A. B. The genetic architecture of Parkinson's disease. *Lancet Neurol.* (2020). doi:10.1016/s1474-4422(19)30287-x
4. Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.* **47**, D1005–D1012 (2019).
5. Nalls, M. A. *et al.* Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol.* **18**, 1091–1102 (2019).
6. Edwards, S. L., Beesley, J., French, J. D. & Dunning, M. Beyond GWASs: Illuminating the dark road from association to function. *American Journal of Human Genetics* **93**, 779–797 (2013).
7. Porcu, E. *et al.* Mendelian randomization integrating GWAS and eQTL data reveals genetic determinants of complex and clinical traits. *Nat. Commun.* **10**, 1–12 (2019).
8. Maurano, M. T. *et al.* Systematic localization of common disease-associated variation in regulatory DNA. *Science (80-.)*. **337**, 1190–1195 (2012).
9. Pierce, S. E. *et al.* Post-GWAS knowledge gap: the how, where, and when. *npj Park. Dis.* **6**, 1–5 (2020).
10. French, J. D. & Edwards, S. L. The Role of Noncoding Variants in Heritable Disease. *Trends Genet.* **0**, (2020).

11. Sassone, J., Colciago, C., Cislighi, G., Silani, V. & Ciammola, A. Huntington's disease: The current state of research with peripheral tissues. *Experimental Neurology* **219**, 385–397 (2009).
12. Horsager, J. *et al.* Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. *Brain* **143**, 3077–3088 (2020).
13. Borghammer, P., Knudsen, K., Fedorova, T. D. & Brooks, D. J. Imaging Parkinson's disease below the neck. *npj Parkinson's Disease* **3**, 1–10 (2017).
14. Wakabayashi, K. Where and how alpha-synuclein pathology spreads in Parkinson's disease: *Neuropathology* **40**, 415–425 (2020).
15. Gelpi, E. *et al.* Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. *Mov. Disord.* **29**, 1010–1018 (2014).
16. Martinez-Valbuena, I. *et al.* Interaction of amyloidogenic proteins in pancreatic β cells from subjects with synucleinopathies. *Acta Neuropathol.* **135**, 877–886 (2018).
17. Homma, T., Mochizuki, Y. & Mizutani, T. Phosphorylated α -synuclein immunoreactivity in the posterior pituitary lobe. *Neuropathology* **32**, 385–389 (2012).
18. Kim, S. *et al.* Transneuronal Propagation of Pathologic α -Synuclein from the Gut to the Brain Models Parkinson's Disease. *Neuron* **103**, 627-641.e7 (2019).
19. Schierding, W. *et al.* Common Variants Coregulate Expression of GBA and Modifier Genes to Delay Parkinson's Disease Onset. *Mov. Disord.* mds.28144 (2020).
doi:10.1002/mds.28144
20. Liu, X., Li, Y. I. & Pritchard, J. K. Trans Effects on Gene Expression Can Drive Omnigenic Inheritance. *Cell* **177**, 1022-1034.e6 (2019).
21. Fadason, T., Schierding, W., Lumley, T. & O'Sullivan, J. M. Chromatin interactions and expression quantitative trait loci reveal genetic drivers of multimorbidities. *Nat. Commun.* **9**, 5198 (2018).

22. Smemo, S. *et al.* Obesity-associated variants within FTO form long-range functional connections with IRX3. *Nature* **507**, 371–375 (2014).
23. Nica, A. C. & Dermitzakis, E. T. Expression quantitative trait loci: Present and future. *Philosophical Transactions of the Royal Society B: Biological Sciences* **368**, (2013).
24. Barnat, M. *et al.* Huntington’s disease alters human neurodevelopment. *Science* (80-.). **793**, eaax3338 (2020).
25. Fadason, T. *et al.* Reconstructing the blood metabolome and genotype using long-range chromatin interactions. *Metab. Open* 100035 (2020).
doi:10.1016/j.metop.2020.100035
26. Aguet, F. *et al.* The GTEx Consortium atlas of genetic regulatory effects across human tissues. *bioRxiv* 787903 (2019). doi:10.1101/787903
27. Kong, S. & Zhang, Y. Deciphering Hi-C: from 3D genome to function. *Cell Biology and Toxicology* **35**, 15–32 (2019).
28. Schmitt, A. D. *et al.* A Compendium of Chromatin Contact Maps Reveals Spatially Active Regions in the Human Genome. *Cell Rep.* **17**, 2042–2059 (2016).
29. Won, H. *et al.* Chromosome conformation elucidates regulatory relationships in developing human brain. *Nature* **538**, (2016).
30. Dixon, J. R. *et al.* Chromatin architecture reorganization during stem cell differentiation. *Nature* **518**, 331–336 (2015).
31. Dunham, I. *et al.* An integrated encyclopedia of DNA elements in the human genome. *Nature* **489**, 57–74 (2012).
32. Walker, R. L. *et al.* Genetic Control of Expression and Splicing in Developing Human Brain Informs Disease Mechanisms. *Cell* **179**, 750-771.e22 (2019).
33. Dayem Ullah, A. Z. *et al.* SNPnexus: assessing the functional relevance of genetic variation to facilitate the promise of precision medicine. *Nucleic Acids Res.* **46**, 109–

- 113 (2018).
34. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434–443 (2020).
35. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in 141,456 humans. *Genome Aggreg. Database Consort.* **19**, (2020).
36. Szklarczyk, D. *et al.* STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res.* **47**, D607–D613 (2019).
37. Blondel, V. D., Guillaume, J. L., Lambiotte, R. & Lefebvre, E. Fast unfolding of communities in large networks. *J. Stat. Mech. Theory Exp.* **2008**, P10008 (2008).
38. Raudvere, U. *et al.* g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). *Nucleic Acids Res.* **47**, W191–W198 (2019).
39. Makarious, M. B. *et al.* Multi-Modality Machine Learning Predicting Parkinson’s Disease. *bioRxiv* **2**, (2021).
40. Grenn, F. P. *et al.* The Parkinson’s Disease Genome-Wide Association Study Locus Browser. *Mov. Disord.* **35**, 2056–2067 (2020).
41. Westra, H.-J. *et al.* Systematic identification of trans eQTLs as putative drivers of known disease associations. *Nat. Genet.* **45**, 1238–1243 (2013).
42. spicuglia, salvatore & Vanhille, L. Chromatin signatures of active enhancers. *Nucleus* **3**, 126–131 (2012).
43. Aguet, F. *et al.* The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science (80-.).* **369**, 1318–1330 (2020).
44. Karczewski, K. J. *et al.* Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. *bioRxiv* 531210 (2019). doi:10.1101/531210

45. Schwamborn, J. C. Is Parkinson's disease a neurodevelopmental disorder and will brain organoids help us to understand it? *Stem Cells Dev.* **27**, 968–975 (2018).
46. Sulzer, D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. *Trends in Neurosciences* **30**, 244–250 (2007).
47. Johnson, M. E., Stecher, B., Labrie, V., Brundin, L. & Brundin, P. Triggers, Facilitators, and Aggravators: Redefining Parkinson's Disease Pathogenesis. *Trends in Neurosciences* **42**, 4–13 (2019).
48. Lage, K. Protein-protein interactions and genetic diseases: The interactome. *Biochimica et Biophysica Acta - Molecular Basis of Disease* **1842**, 1971–1980 (2014).
49. Yoshida, H. & Goedert, M. Phosphorylation of microtubule-associated protein tau by AMPK-related kinases. *J. Neurochem.* **120**, 165–176 (2012).
50. Fasano, D. *et al.* Alteration of endosomal trafficking is associated with early-onset parkinsonism caused by SYNJ1 mutations. *Cell Death Dis.* **9**, 1–15 (2018).
51. Quadri, M. *et al.* Mutation in the SYNJ1 Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism. *Hum. Mutat.* **34**, 1208–1215 (2013).
52. Le Clainche, C. *et al.* A Hip1R–cortactin complex negatively regulates actin assembly associated with endocytosis. *EMBO J.* **26**, 1199–1210 (2007).
53. Wilbur, J. D. *et al.* Actin Binding by Hip1 (Huntingtin-interacting Protein 1) and Hip1R (Hip1-related Protein) Is Regulated by Clathrin Light Chain. (2008).
doi:10.1074/jbc.M802863200
54. Yang, Q. *et al.* Endocytic adaptor protein HIP1R controls intracellular trafficking of epidermal growth factor receptor in neuronal dendritic development. *Front. Mol. Neurosci.* **11**, 1–17 (2018).
55. Shen, X. G. *et al.* Retinoic Acid-Induced Protein 14 (RAI14) Promotes mTOR-Mediated Inflammation Under Inflammatory Stress and Chemical Hypoxia in a U87

- Glioblastoma Cell Line. *Cell. Mol. Neurobiol.* **39**, 241–254 (2019).
56. Wolf, D. *et al.* Ankyrin repeat-containing N-Ank proteins shape cellular membranes. *Nat. Cell Biol.* **21**, 1191–1205 (2019).
 57. Orr, C. F., Rowe, D. B. & Halliday, G. M. An inflammatory review of Parkinson's disease. *Progress in Neurobiology* **68**, 325–340 (2002).
 58. Clark, J. N., Whiting, A. & McCaffery, P. Retinoic acid receptor-targeted drugs in neurodegenerative disease. *Expert Opin. Drug Metab. Toxicol.* **16**, 1097–1108 (2020).
 59. Bae, E. J. *et al.* LRRK2 kinase regulates α -synuclein propagation via RAB35 phosphorylation. *Nat. Commun.* **9**, (2018).
 60. Beach, T. G. *et al.* Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. *Acta Neuropathol.* **119**, 689–702 (2010).
 61. Mohammadi, S., Dolatshahi, M. & Rahmani, F. Shedding light on thyroid hormone disorders and Parkinson disease pathology: mechanisms and risk factors. *Journal of Endocrinological Investigation* 1–13 (2020). doi:10.1007/s40618-020-01314-5
 62. Mohammadi, S., Dolatshahi, M. & Rahmani, F. Shedding light on thyroid hormone disorders and Parkinson disease pathology: mechanisms and risk factors. *Journal of Endocrinological Investigation* 1–13 (2020). doi:10.1007/s40618-020-01314-5
 63. Chen, S. F., Yang, Y. C., Hsu, C. Y. & Shen, Y. C. Risk of Parkinson's disease in patients with hypothyroidism: A nationwide population-based cohort study. *Park. Relat. Disord.* **74**, 28–32 (2020).
 64. Houser, M. C. & Tansey, M. G. The gut-brain axis: Is intestinal inflammation a silent driver of Parkinson's disease pathogenesis? *npj Parkinson's Disease* **3**, 1–9 (2017).
 65. Suttrup, I. *et al.* Esophageal dysfunction in different stages of Parkinson's disease. *Neurogastroenterol. Motil.* **29**, e12915 (2017).

66. Wu, Z. Q. *et al.* Caspr Controls the Temporal Specification of Neural Progenitor Cells through Notch Signaling in the Developing Mouse Cerebral Cortex. *Cereb. Cortex* **27**, 1369–1385 (2017).
67. Spratley, S. J. *et al.* Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants. *Traffic* **17**, 908–922 (2016).
68. Marshall, M. S. & Bongarzone, E. R. Beyond Krabbe’s disease: The potential contribution of galactosylceramidase deficiency to neuronal vulnerability in late-onset synucleinopathies. *J. Neurosci. Res.* **94**, 1328–1332 (2016).
69. Sun, Y., Curle, A. J., Haider, A. M. & Balmus, G. The role of DNA damage response in amyotrophic lateral sclerosis. *Essays in Biochemistry* **64**, 847–861 (2020).
70. Wu, J., Lu, L. Y. & Yu, X. The role of BRCA1 in DNA damage response. *Protein and Cell* **1**, 117–123 (2010).
71. Liaw, H., Lee, D. & Myung, K. DNA-PK-dependent RPA2 hyperphosphorylation facilitates DNA repair and suppresses sister chromatid exchange. *PLoS One* **6**, 21424 (2011).
72. Wu, W. *et al.* Neuronal enhancers are hotspots for DNA single-strand break repair. *Nature* (2021). doi:10.1038/s41586-021-03468-5
73. Mei, Y. *et al.* Identification of BECN1 and ATG14 Coiled-Coil Interface Residues That Are Important for Starvation-Induced Autophagy. *Biochemistry* **55**, 4239–4253 (2016).
74. Tan, E. K. *et al.* Parkinson disease and the immune system — associations, mechanisms and therapeutics. *Nature Reviews Neurology* **16**, 303–318 (2020).
75. Yu, E. *et al.* Fine mapping of the HLA locus in Parkinson’s disease in Europeans. *medRxiv* 2020.10.29.20217059 (2020). doi:10.1101/2020.10.29.20217059
76. Koussounadis, A., Langdon, S. P., Um, I. H., Harrison, D. J. & Smith, V. A.

Relationship between differentially expressed mRNA and mRNA-protein correlations
in a xenograft model system. *Sci. Rep.* **5**, 1–9 (2015).

Figures

Figure 1: Methods workflow. 90 PD-SNPs were obtained from Nalls et al⁵. Spatial interactions between the 90 PD-SNPs and genes were identified from Hi-C libraries (Supplementary table 2). The resulting spatial SNP-gene pairs were then used to query GTEx v8 to identify significant eQTLs. The resulting SNP-gene pairs were then analysed for functional relevance using multiple tools and databases (methods). Figure adapted from Schierding et al.¹⁹

*All eQTLs-
regulation*

Cis- regulation

*Trans-
intrachromosomal-
regulation*

*Trans-
interchromosomal-
regulation*

Figure 2: Correlation between genotype samples per tissue and number of

eQTLs present in the tissue (a) Correlation between the number of genotyped samples per tissue (in GTEx) and the number of eQTLs (including cis, trans-intrachromosomal and trans-interchromosomal) per tissue, in 13 brain-specific tissues (b) Correlation between the number of genotyped samples per tissue (in GTEx) and the number of cis-eQTLs per tissue, in 13 brain-specific tissues (c) Correlation between the number of genotyped samples per tissue (in GTEx) and the number of trans-intrachromosomal-eQTLs per tissue, in 13 brain-specific tissues (d) Correlation between the number of genotyped samples per tissue (in GTEx) and the number of trans-interchromosomal-eQTLs per tissue, in 13 brain-specific tissues (e) Correlation between the number of genotyped samples per tissue (in GTEx) and the number of eQTLs (including cis, trans-intrachromosomal and trans-interchromosomal) per tissue, in all 49 tissues (f) Correlation between the number of genotyped samples per tissue (in GTEx) and the number of cis-eQTLs per tissue, in all 49 tissues (g) Correlation between the number of genotyped samples per tissue (in GTEx) and the number of trans-intrachromosomal-eQTLs per tissue, in all 49 tissues (h) Correlation between the number of genotyped samples per tissue (in GTEx) and the number of trans-interchromosomal-eQTLs per tissue, in all 49 tissues. The tissues that fall furthest from the confidence interval are annotated. The grey dots show the correlation for all GTEx tissues. The 13 brain tissues (from GTEx) are indicated by the coloured dots, as shown in the legend. For information on all tissues outside of the 95% CI see Supplementary table 12.

Figure 3: Genes subjected to trans-regulation by PD-SNPs are enriched for Loss-of-Function Intolerance. Genes that are loss of function intolerant, as measured by a continuous LOEUF score, are enriched in *trans*-regulatory interactions involving PD-SNPs. The LOEUF score is a continuous value that indicates the tolerance of a given gene to inactivation. Low LOEUF scores indicate stronger selection against loss-of-function variation. The distribution is shown as a violin plot with the median (LOEUF) values for each eQTL group (black text). The groups were compared using a Kruskal-Wallis test (** = P value < 0.01); the absence of a significance value indicates the LOEUF values of the two groups were not significantly different. No eQTL = all genes in gnomAD with an assigned pLI or LOEUF for which an eQTL was not identified in this study (~18,500 genes). Not all genes had LOEUF scores (Supplementary figure 2; Supplementary table 7)

Figure 4: Gene regulation in the foetal cortex compared to the adult cortex. The leftmost section shows genes that are regulated only in the foetal cortex, with no eQTLs seen in any of the 13 adult brain tissues. The middle section shows genes that are regulated in both the foetal and adult cortex. The black dots show the regulation effect size of the gene in the adult cortex, and the grey dots show the regulation effect size of the gene across the different brain tissues (where an eQTL is seen). The rightmost section shows genes that are regulated in both the foetal cortex and adult non-cortical brain tissue.

Figure 5: Louvain Clustering analysis highlights nine significant clusters,

indicative of biological connectivity. The grey and orange shading of the nodes is

indicative of whether the gene is subject to regulation via *cis*- or *trans*- mechanisms. The pink and turquoise shaded circles indicate genes that are regulated in adult brain tissue and foetal cortex respectively. STRING PPI confidence level = high (0.700); text-mining connections removed. The clusters were also analysed in STRING with an increased stringency (including only experimentally determined and curated database connections, confidence level: 0.700); however, this led to very few changes, with cluster 6 the only cluster to lose any connectivity within the cluster (WDHD1, NCAPG and PARPBP no longer connect). Experimentally determined: imported from experimental repositories; Gene neighbourhood: similar genomic context in different species suggest a similar function of the proteins; Gene fusions: fused proteins are recognised by orthology of the fused parts to other, non-fused proteins; Gene co-occurrence: indicates the presence of a specific gene pair is in agreement in all species – must be expressed together; Co-expression: predicted association between genes/proteins based on RNA and/or protein expression.

Supplementary Figures

Supplementary figure 1: Number of genes regulated per SNP. Each of the 76 SNPs has an eQTL with between 1 and 39 genes. The boxplot represents the median and interquartile range.

Supplementary figure 2: The proportion of genes that are loss of function

intolerant increases as the eQTL distance increases. Not all genes have an assigned LOEUF score. The plot shows the percentage of genes that have no assigned score for each of the eQTL categories.

Supplementary figure 3: Genes subject to regulation in non-CNS tissues only. Our

analysis identified a subset of 21 PD GWAS SNPs that regulate genes only within non-CNS tissues (*i.e.* these SNPs had no regulatory connections within brain tissues).

Supplementary figure 4: SNPs co-regulate multiple genes within individual

clusters. For each of the seven clusters there is at least one SNP that co-regulates more than one of the genes within that cluster. The SNPs do not co-regulate the genes in the same direction in most instances. In some cases where the SNP regulates the expression of one gene in multiple tissues, the regulation may be positive in some tissues, but negative in others. For example expression of STBD1 is down-regulated in 7 tissues but up-regulated in the testis and lung.

Supplementary figure 5: Genes and variants identified by Makarios et al

connect into clusters 1, 2, 4 and 5. Makarios et al identified a set of genes and variants that affect the polygenic risk score for diagnosis of PD. A subset of these genes connect into the clusters identified through our analysis, showing a convergence between the two datasets, and further confirming the importance of the enriched pathways to PD biology. Adapted from main figure 5. The green shading of the nodes indicates genes that are identified from the Makarios et al dataset.